Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Mechanical model of brain convolutional development.
International consensus guidance for management of myasthenia gravis
An international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide is developed. Expand
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled,…
A phase 3, randomised, double-blind, placebo-controlled, multicentre study in 76 hospitals and specialised clinics across North America, Latin America, Europe, and Asia to assess the efficacy and safety of eculizumab in patients with refractory myasthenia gravis. Expand
Neuromuscular transmission in amyotrophic lateral sclerosis
The functional and structural characteristics of the neuromuscular junction were studied in anconeus muscle biopsies of 10 patients with amyotrophic lateral sclerosis (ALS) and decreased amplitudes of miniature endplate potentials (MEPPs) revealed. Expand
A genome-wide association study of myasthenia gravis.
The genetic data provide insights into aberrant cellular mechanisms responsible for this prototypical autoimmune disorder and suggest that clinical trials of immunomodulatory drugs related to CTLA4 and that are already Food and Drug Administration approved as therapies for other autoimmune diseases could be considered for patients with refractory disease. Expand
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis
Initiation of mycophenolate mofetil treatment was not superior to placebo in maintaining myasthenia gravis control during a 36-week schedule of prednisone tapering, but MMF was well tolerated and adverse events were consistent with previous studies. Expand
Treatment of autoimmune myasthenia gravis
Immune-directed treatment of patients with MG is aimed at inducing an immunologic remission and then maintaining that remission, usually accomplished by slow tapering of the corticosteroids along with the use of “steroid-sparing” agents, which include azathioprine, thymectomy, and possibly mycophenolate. Expand
Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.
Findings support the role of MuSK antibodies in the human disease, demonstrate the roleof MuSK not only in the development of the NMJ but also in the maintenance of the mature synapse, and demonstrate involvement of this disease in both presynaptic and postsynaptic components of theNMJ. Expand
Treatment of Myasthenia Gravis Based on Its Immunopathogenesis
The prognosis of myasthenia gravis has improved dramatically due to advances in critical-care medicine and symptomatic treatments, but the treatment of MG has been based primarily on experience rather than gold-standard evidence from randomized controlled trials. Expand
Myasthenia gravis and related disorders: Pathology and molecular pathogenesis.
This review focuses on the various molecular and pathophysiological mechanisms of these disorders, characterization of which has been crucial to the development of treatment strategies specific for each pathogenic mechanism. Expand